Corvus Pharmaceuticals (CRVS) stock
Follow CRVS's trial news. Pro members can get an alert when Corvus Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
CRVS's Quality Score rose 1 point on Fri, Oct 2, to -4.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live. So can you, free, with no account.
What's next for CRVS, and how long its cash lasts
From Corvus Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into the second quarter of 2028 (8-K, Aug 6).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Mar 13, 2026)
- At-the-market share sales program (424B5, filed Mar 13, 2026)
Insiders
Director David Scott Moore bought 21,700 shares on Jun 11. 1 more insider trade this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 26 daysINOInovio Pharmaceuticals
INOINO-3107
- In 37 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 49 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 28% in 3 months, 19% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−1Long-term trend below a falling 200-day average
4 more things pulling CRVS's score down, for Pro members
What's next
Expected to report Tue Nov 3, after the close
After its last 4 reports it closed +0.3% on average, higher 2 of 4 times.
What would turn CRVS's score around: 8 things, for Pro members
Here is what Pro members see.
See it live, free until Tuesday morning. No account. No card. Then keep going with a free account. Every stock ranked for you.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
CRVS has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1430.7
- MACD (12, 26, 9)Below signal
- 50-day average$13.49
- 200-day average$14.15
- ADX 1421.6
- Support$10.83
- Resistance$13.46
- Bollinger Bands (20, 2)Inside
- Volume1.1x
How CRVS ranks in Biotech
CRVS is #225 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
CRLOpen for its score
CRSPOpen for its score
CTNMOpen for its score
CUEOpen for its score
CRVS1/14-4
When does CRVS report earnings, and what happens after?
Expected to report Tue Nov 3, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | -6.9% | +0.4% | +9.2% |
| May 7, 2026After close | After close | +1.5% | +6.6% | -6.4% |
| Mar 12, 2026After close | After close | -1.7% | -4.3% | -12.0% |
| Nov 4, 2025After close | After close | -1.3% | -1.4% | +6.9% |
Who is trading CRVS
CRVS insider trades
One insider bought $250K across 1 filing in the last 6 months. No open-market sales on record. The newest:
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of CRVS's score, with the points and the reason
- All 14 checks on CRVS and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on CRVS
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.